Ribociclib, approved by the USFDA on March 13, 2017, in order to treat HR +/HER2 − advanced/metastatic breast cancer, along with an aromatase inhibitor in postmenopausal women. The ribociclib price varies from branded to non-branded (generic) drugs. Ribociclib is taken on a 4-week dosing cycle. For the initial 3 weeks in a cycle, ribociclib is administered once daily. In the 4'th week, the pills of ribociclib won't be administered. In case patients are taking an oral NSAI, it should be taken with ribociclib for the initial 3 weeks, and alone for the 4'th week.